EXTON, Pa.--(BUSINESS WIRE)-- The LaunchTrends®: Teflaro Wave 3 report, which measures product uptake and commercial effectiveness at twelve months post launch, finds that over half of Infectious Disease (ID) specialists and 41 percent of internists that report awareness of Forest/ AstraZeneca/Dainippon Sumitomo’s Teflaro have initiated use of the drug. The majority of use is for patients with complicated Skin and Skin Structure Infections (cSSSIs)/acute bacterial SSSIs (ABSSSIs).
Overall, surveyed physicians have a favorable initial reaction to Teflaro and report that they are willing to prescribe it. More physicians report a willingness to prescribe Teflaro for the management of cSSSIs/ABSSSIs than for Community-acquired bacterial pneumonia (CABP). According to a quarter of ID specialists surveyed Teflaro’s Methicillin-resistant Staphylococcus aureus (MRSA) activity is perceived as a key advantage of the drug for treatment of both ABSSSIs and CABP, even though Teflaro is not FDA approved for use in CABP due to MRSA.
“Our analysis points to formulary access and lack of familiarity as key challenges to the uptake of Teflaro in the hospital antibiotic market,” said BioTrends Infectious Diseases Associate Therapeutic Class Director Brenda Perez-Cheeks, Ph.D. “Over half of Teflaro non-prescribers report not having the drug on their hospital’s formularies as compared to 15 percent of Teflaro prescribers.”
In addition, this study finds that when Teflaro is included on hospital formularies, its use is frequently subjected to approval restrictions by infection type and specialty. Further, surveyed internists report having more difficultly accessing Teflaro as compared to ID specialists.
Regarding awareness of late stage products in development that have MRSA activity, overall surveyed physicians had low to moderate awareness. Physicians were most aware of Durata’s dalbavancin and Basilea’s ceftobiprole.
About LaunchTrends®
LaunchTrends®: Teflaro is a three-wave syndicated report series designed to track perceptions and anticipated use of Teflaro at three months, six months, and twelve months following launch. LaunchTrends® assesses trial and use of new products, barriers to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages, and product satisfaction. In the current wave of research, BioTrends and AMR surveyed 51 ID specialists and 50 internists and conducted qualitative interviews with a subset of 15 of the survey responders in March 2012. BioTrends will continue to track the uptake of Teflaro in addition to other key Serious Gram-Positive Infections therapies in TreatmentTrends: MRSA and Serious Gram-Positive Infections (US) report publishing in June 2012.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends Research Group is a Decision Resources Group company.
About Arlington Medical Resources, LLC
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drugs with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
CONTACT:
BioTrends Research Group, LLC
Brenda Perez-Cheeks, Ph.D., 610-908-7255
[email protected]
or
Decision Resources Group
Lisa Osgood, 781-993-2606
[email protected]
KEYWORDS: United States North America Pennsylvania
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Pharmaceutical General Health
MEDIA:
| Logo |